Co-Authors
This is a "connection" page, showing publications co-authored by Hadi Yassine and Laith Abu-Raddad.
Connection Strength
2.778
-
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J Travel Med. 2021 10 11; 28(7).
Score: 0.243
-
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. Clin Infect Dis. 2021 10 05; 73(7):e1830-e1840.
Score: 0.243
-
Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar. JAMA. 2021 07 13; 326(2):185-188.
Score: 0.239
-
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021 09; 27(9):1614-1621.
Score: 0.239
-
Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. Sci Rep. 2021 06 04; 11(1):11837.
Score: 0.237
-
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. iScience. 2021 Jun 25; 24(6):102646.
Score: 0.237
-
Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. Emerg Infect Dis. 2021 05; 27(5):1343-1352.
Score: 0.236
-
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine. 2021 May; 35:100861.
Score: 0.236
-
Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. BMJ Innov. 2021 Apr; 7(2):327-336.
Score: 0.234
-
Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. Infect Genet Evol. 2021 03; 88:104684.
Score: 0.230
-
Performance evaluation of five ELISA kits for detecting anti-SARS-COV-2 IgG antibodies. Int J Infect Dis. 2021 Jan; 102:181-187.
Score: 0.228
-
Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays. Front Biosci (Landmark Ed). 2021 07 30; 26(7):198-206.
Score: 0.060
-
SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. Open Forum Infect Dis. 2021 Aug; 8(8):ofab221.
Score: 0.059
-
Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 Individuals. Microorganisms. 2021 Jan 25; 9(2).
Score: 0.058